Literature DB >> 10182190

The role of pharmacoeconomic evaluations in disease management.

K Chang1, D Nash.   

Abstract

Disease management is a systematic approach to a health condition or a healthcare intervention that organises preventative, interventional and care approaches throughout the continuum of care and which measures outcomes in terms of populations, not individuals. Disease management's advantage over the current component system is that it stresses prevention over acute treatment of a chronic disease. Patients with better control of their chronic diseases will likely have a decrease in the use of emergency room and inpatient hospitalisation services, thereby improving clinical outcomes of patients. To achieve these goals, disease management uses pharmacoeconomic evaluations and outcomes measures to provide information that helps build formularies and clinical practice guidelines. Several problems exist in integrating pharmacoeconomic studies in disease management models, such as the need for more integrated information systems, standardisation and who should perform these evaluations. Some possible solutions will be addressed in this article. With greater emphasis being placed on controlling costs, the need for pharmacoeconomic evaluations in the design of disease management models will continue to increase in the future.

Entities:  

Mesh:

Year:  1998        PMID: 10182190     DOI: 10.2165/00019053-199814010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  10 in total

1.  The role of physicians in disease management.

Authors:  P Wynn
Journal:  Manag Care       Date:  1996-10

2.  Does disease management work?

Authors:  D P Pasternak; J M Harris
Journal:  Physician Exec       Date:  1996-12

3.  Using disease state management to coordinate care across the continuum.

Authors:  E Zablocki
Journal:  Qual Lett Healthc Lead       Date:  1995-11

4.  Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

Authors:  A L Hillman; J M Eisenberg; M V Pauly; B S Bloom; H Glick; B Kinosian; J S Schwartz
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

5.  Disease management ... drug data debate.

Authors:  L Muir
Journal:  Hosp Health Netw       Date:  1997-06-05

6.  Practical issues in conducting pharmacoeconomic studies.

Authors:  R Rajagopalan; J E Kallal; J F Fowler; E F Sherertz
Journal:  Clin Ther       Date:  1996 Nov-Dec       Impact factor: 3.393

7.  Is there a need for standardization of methods in economic evaluations of medicine?

Authors:  B E Rittenhouse
Journal:  Med Care       Date:  1996-12       Impact factor: 2.983

8.  The future of pharmacoeconomics: bridging science and practice.

Authors:  M F Drummond
Journal:  Clin Ther       Date:  1996 Sep-Oct       Impact factor: 3.393

Review 9.  Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) and RADIANCE (Randomized Assessment of Digoxin on Inhibitors of the angiotensin Converting Enzyme) trials.

Authors:  J Tauke; S Goldstein; M Gheorghiade
Journal:  Prog Cardiovasc Dis       Date:  1994 Jul-Aug       Impact factor: 8.194

10.  Disease management interventions to improve outcomes in congestive heart failure.

Authors:  J L Roglieri; R Futterman; K L McDonough; G Malya; K R Karwath; D Bowman; J Skelly; S W Warburton
Journal:  Am J Manag Care       Date:  1997-12       Impact factor: 2.229

  10 in total
  2 in total

1.  Pharmacoeconomic analyses using discrete event simulation.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

2.  Impact of Integrated Care Model (ICM) on Direct Medical Costs in Management of Advanced Chronic Obstructive Pulmonary Disease (COPD).

Authors:  Ewa Bandurska; Iwona Damps-Konstańska; Piotr Popowski; Tadeusz Jędrzejczyk; Piotr Janowiak; Katarzyna Świętnicka; Marzena Zarzeczna-Baran; Ewa Jassem
Journal:  Med Sci Monit       Date:  2017-06-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.